TY - JOUR
T1 - Allogeneic stem cell transplantation in first complete remission
AU - Oran, Betul
AU - Weisdorf, Daniel J
PY - 2011/11
Y1 - 2011/11
N2 - Purpose of review: The optimal postremission therapy of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. This review summarizes the recent developments in the clinical research and therapeutic applications defining the role of allogeneic hematopoietic stem cell transplantation (allo-HCT) in CR1. RECENT FINDINGS: Molecular markers in combinations with cytogenetics have improved the risk stratification and informed decision-making in patients with AML in CR1. In parallel, several important advances in the transplant field, such as better supportive care, improved transplant technology, increased availability of alternative donors, and reduced-intensity conditioning, have improved the safety as well as access of allo-HCT for a larger number of patients. Summary: The progress in risk stratification and in transplant technology dictate that early donor identification search should be initiated for all eligible AML patients in CR1.
AB - Purpose of review: The optimal postremission therapy of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. This review summarizes the recent developments in the clinical research and therapeutic applications defining the role of allogeneic hematopoietic stem cell transplantation (allo-HCT) in CR1. RECENT FINDINGS: Molecular markers in combinations with cytogenetics have improved the risk stratification and informed decision-making in patients with AML in CR1. In parallel, several important advances in the transplant field, such as better supportive care, improved transplant technology, increased availability of alternative donors, and reduced-intensity conditioning, have improved the safety as well as access of allo-HCT for a larger number of patients. Summary: The progress in risk stratification and in transplant technology dictate that early donor identification search should be initiated for all eligible AML patients in CR1.
KW - acute myeloid leukemia
KW - allogeneic stem cell transplantation
KW - first complete remission
UR - http://www.scopus.com/inward/record.url?scp=80054764353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054764353&partnerID=8YFLogxK
U2 - 10.1097/MOH.0b013e32834ba94c
DO - 10.1097/MOH.0b013e32834ba94c
M3 - Review article
C2 - 21912256
AN - SCOPUS:80054764353
SN - 1065-6251
VL - 18
SP - 395
EP - 400
JO - Current opinion in hematology
JF - Current opinion in hematology
IS - 6
ER -